[HTML][HTML] Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α–AKT–mTOR …

YM Wang, X Xu, J Tang, ZY Sun, YJ Fu, XJ Zhao… - Cell & Bioscience, 2021 - Springer
Background Apatinib, a novel vascular endothelial growth factor receptor-2 (VEGFR-2)
tyrosine kinase inhibitor, has been approved for the treatment of metastatic gastric cancer …

Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1 [alpha]-AKT-mTOR …

YM Wang, X Xu, J Tang, ZY Sun, YJ Fu, XJ Zhao… - Cell & …, 2021 - go.gale.com
Background Apatinib, a novel vascular endothelial growth factor receptor-2 (VEGFR-2)
tyrosine kinase inhibitor, has been approved for the treatment of metastatic gastric cancer …

Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α–AKT–mTOR pathway in …

YM Wang, X Xu, J Tang, ZY Sun, YJ Fu… - Cell & …, 2021 - search.ebscohost.com
Background: Apatinib, a novel vascular endothelial growth factor receptor-2 (VEGFR-2)
tyrosine kinase inhibitor, has been approved for the treatment of metastatic gastric cancer …

Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α–AKT–mTOR pathway in …

W Yu-Ming, X Xu, J Tang, ZY Sun, F Yu-Jie… - Cell & …, 2021 - search.proquest.com
Background Apatinib, a novel vascular endothelial growth factor receptor-2 (VEGFR-2)
tyrosine kinase inhibitor, has been approved for the treatment of metastatic gastric cancer …

Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α-AKT-mTOR pathway in …

YM Wang, X Xu, J Tang, ZY Sun, YJ Fu… - Cell & …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Apatinib, a novel vascular endothelial growth factor receptor-2 (VEGFR-2)
tyrosine kinase inhibitor, has been approved for the treatment of metastatic gastric cancer …

[HTML][HTML] Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α–AKT–mTOR …

YM Wang, X Xu, J Tang, ZY Sun, YJ Fu, XJ Zhao… - Cell & …, 2021 - ncbi.nlm.nih.gov
Background Apatinib, a novel vascular endothelial growth factor receptor-2 (VEGFR-2)
tyrosine kinase inhibitor, has been approved for the treatment of metastatic gastric cancer …

Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α–AKT–mTOR pathway in …

YM Wang, X Xu, J Tang, ZY Sun, YJ Fu, XJ Zhao… - 2021 - agris.fao.org
Background Apatinib, a novel vascular endothelial growth factor receptor-2 (VEGFR-2)
tyrosine kinase inhibitor, has been approved for the treatment of metastatic gastric cancer …

[HTML][HTML] Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α–AKT–mTOR …

YM Wang, X Xu, J Tang, ZY Sun… - Cell & …, 2021 - cellandbioscience.biomedcentral …
Apatinib, a novel vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase
inhibitor, has been approved for the treatment of metastatic gastric cancer and other tumors …

[PDF][PDF] Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α–AKT–mTOR …

YM Wang, X Xu, J Tang, ZY Sun, YJ Fu, XJ Zhao… - 2021 - scholar.archive.org
Background: Apatinib, a novel vascular endothelial growth factor receptor‑2 (VEGFR‑2)
tyrosine kinase inhibitor, has been approved for the treatment of metastatic gastric cancer …

Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α-AKT-mTOR pathway in …

YM Wang, X Xu, J Tang, ZY Sun, YJ Fu, XJ Zhao… - Cell & …, 2021 - europepmc.org
Background Apatinib, a novel vascular endothelial growth factor receptor-2 (VEGFR-2)
tyrosine kinase inhibitor, has been approved for the treatment of metastatic gastric cancer …